The effects of polycystic ovarian syndrome (PCOS) on women's health and happiness are substantial. Traditional medicines and natural products have gained popularity as potential anti-PCOS therapy due to their efficacy with fewer side effects. To properly map the molecular targets of natural products against a wide variety of illnesses, including PCOS, it has become obvious that network pharmacology investigations will be required. The purpose of this study was to use network pharmacology to better understand the pharmacological underpinnings of the action of the Vitexdoins family in the treatment of PCOS. Both the primary Vitexdoin family and its putative targets were retrieved from the PubChem and SwissTargetPrediction databases. The GeneCards and STRING databases were scoured for PCOS-related genes and known protein-protein interaction networks. Finally, Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analyses were used to discover the mechanism of action of Vitexdoins by identifying important pathways and functions of these networks. The Vitexdoins family consists of 5 compounds, and these compounds matched 116 PCOS-related targets. The most important core targets of Vitexdoins against PCOS were further analyzed and found to be SRC, HSP90AA1, PIK3CA, EGFR, and STAT3. A total of 10 important pathways in PCOS and its treatment were found by pathway enrichment analysis. These included the pathway of EGFR tyrosine kinase inhibitors, endocrine resistance, PI3K-AKT, focal adhesion, and progesterone-mediated oocyte maturation. In conclusion, our network pharmacological study provides a theoretical framework for future investigations into the possible anti-PCOS effects of the Vitexdoins family